Free Trial

Galectin Therapeutics (GALT) Competitors

Galectin Therapeutics logo
$1.53 +0.12 (+8.51%)
Closing price 02/18/2025 04:00 PM Eastern
Extended Trading
$1.56 +0.03 (+1.90%)
As of 02/18/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GALT vs. CRVS, PRME, ATYR, MNPR, TRVI, ALLO, CMPS, KRRO, OLMA, and FHTX

Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Corvus Pharmaceuticals (CRVS), Prime Medicine (PRME), Atyr PHARMA (ATYR), Monopar Therapeutics (MNPR), Trevi Therapeutics (TRVI), Allogene Therapeutics (ALLO), COMPASS Pathways (CMPS), Korro Bio (KRRO), Olema Pharmaceuticals (OLMA), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.

Galectin Therapeutics vs.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.

Galectin Therapeutics' return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus PharmaceuticalsN/A -70.71% -45.90%
Galectin Therapeutics N/A N/A -163.15%

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$27.03M-$0.93-5.13
Galectin TherapeuticsN/AN/A-$41.07M-$0.73-2.10

Corvus Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Galectin Therapeutics received 56 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. However, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 59.11% of users gave Galectin Therapeutics an outperform vote.

CompanyUnderperformOutperform
Corvus PharmaceuticalsOutperform Votes
291
61.91%
Underperform Votes
179
38.09%
Galectin TherapeuticsOutperform Votes
347
59.11%
Underperform Votes
240
40.89%

Corvus Pharmaceuticals presently has a consensus target price of $12.38, suggesting a potential upside of 159.43%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 618.95%. Given Galectin Therapeutics' higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Corvus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Galectin Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Galectin Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Galectin Therapeutics and 1 mentions for Corvus Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 0.20 beat Corvus Pharmaceuticals' score of -0.50 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Corvus Pharmaceuticals Negative
Galectin Therapeutics Neutral

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GALT vs. The Competition

MetricGalectin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$88.49M$6.91B$5.80B$9.22B
Dividend YieldN/A2.89%5.27%3.98%
P/E RatioN/A3.3518.7915.83
Price / SalesN/A352.99479.0583.70
Price / CashN/A75.6346.0538.28
Price / Book-1.515.547.145.01
Net Income-$41.07M$164.55M$3.20B$220.98M
7 Day Performance16.79%1.73%1.38%2.13%
1 Month Performance23.39%1.38%3.47%1.63%
1 Year Performance-12.07%-0.12%20.17%16.41%

Galectin Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GALT
Galectin Therapeutics
1.293 of 5 stars
$1.53
+8.5%
$11.00
+619.0%
-12.1%$88.49MN/A0.009News Coverage
High Trading Volume
CRVS
Corvus Pharmaceuticals
2.2774 of 5 stars
$5.03
-3.5%
$12.38
+146.0%
+108.3%$323.23MN/A-5.4130
PRME
Prime Medicine
3.1063 of 5 stars
$2.42
-2.0%
$13.13
+442.4%
-64.7%$317.41MN/A-1.18234Gap Up
ATYR
Atyr PHARMA
2.2792 of 5 stars
$3.78
-3.2%
$19.25
+409.9%
N/A$316.87M$350,000.00-4.0253Analyst Forecast
Short Interest ↑
News Coverage
Gap Up
MNPR
Monopar Therapeutics
1.3954 of 5 stars
$51.89
+7.1%
$43.00
-17.1%
+2,475.6%$316.53MN/A-26.3410
TRVI
Trevi Therapeutics
2.9568 of 5 stars
$4.06
-4.4%
$9.31
+129.7%
+54.6%$311.71MN/A-9.2220Analyst Revision
Positive News
ALLO
Allogene Therapeutics
2.9449 of 5 stars
$1.49
-1.7%
$9.73
+555.4%
-40.9%$311.36M$90,000.00-0.95310News Coverage
Gap Up
CMPS
COMPASS Pathways
1.8028 of 5 stars
$4.48
+1.6%
$33.60
+650.0%
-57.8%$306.52MN/A-2.04120Analyst Revision
Gap Up
KRRO
Korro Bio
0.9618 of 5 stars
$32.23
-6.9%
$144.00
+346.8%
-44.0%$302.00MN/A0.0070
OLMA
Olema Pharmaceuticals
3.2481 of 5 stars
$5.16
-9.3%
$28.75
+457.2%
-66.4%$295.67MN/A-2.3670News Coverage
FHTX
Foghorn Therapeutics
2.9252 of 5 stars
$5.29
+11.4%
$13.17
+148.9%
-8.6%$294.18M$34.15M-2.76120Short Interest ↑
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners